Vaccines and other immunological approaches for cancer immunoprevention

Current Drug Targets

Volumn 12, Issue 13, 2011, Pages 1957-1973

  Lollini, Pier Luigi ^a   Nicoletti, Giordano ^b   Landuzzi, Lorena ^b   Cavallo, Federica ^c   Forni, Guido ^c   de Giovanni, Carla ^a   Nanni, Patrizia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Antibodies; Cancer vaccines; ErbB2; Immunoprevention; Mammary carcinoma; Oncoantigens; Viral tumors

Indexed keywords

CANCER VACCINE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPSTEIN BARR VIRUS VACCINE; GEMCITABINE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; MAREK DISEASE VACCINE; PEPTIDE VACCINE; PROTEIN RET; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; TAMOXIFEN; TUMOR ANTIGEN; VACCINIA VACCINE; WART VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE HEPATITIS; ANTIGENICITY; ARTICLE; BREAST CARCINOMA; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CELL MATURATION; CHRONIC HEPATITIS; CHRONIC INFLAMMATION; CROSS REACTION; DNA REPAIR; DRUG EFFICACY; DRUG POTENCY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GASTROINTESTINAL POLYPOSIS; GENETIC RISK; HEAD AND NECK TUMOR; HUMAN; HUMORAL IMMUNITY; IMMUNOSURVEILLANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAREK DISEASE; MASS SCREENING; MOLECULAR DIAGNOSIS; NATURAL KILLER CELL; NONHUMAN; PANCREAS ADENOCARCINOMA; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PAROTID GLAND CARCINOMA; PASSIVE IMMUNIZATION; PERSISTENT VIRUS INFECTION; PRIMARY PREVENTION; RISK REDUCTION; SECONDARY PREVENTION; SEXUAL TRANSMISSION; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA; VIREMIA; VIRUS CARCINOGENESIS;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOLOGIC SURVEILLANCE; INFECTION; INFECTION CONTROL; MICE; MICE, TRANSGENIC; NEOPLASMS;

EID: 79953835805     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798184146     Document Type: Article

References (143)

1. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-60.
2. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974; 183: 534-6.
3. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-11.
4. Finn OJ. Cancer immunology. N Engl J Med 2008; 358: 2704-15.
5. Cavallo F, De Giovanni C., Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 2011; 60: 319-26.
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
7. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67.
8. Schulz TF. Cancer and viral infections in immunocompromised individuals. Int J Cancer 2009; 125: 1755-63.
9. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009; 125: 1747-54.
10. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450: 903-7.
11. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008; 371: 771-83.
12. Muller-Hermelink N, Braumuller H, Pichler B, et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008; 13: 507-18.
13. Beatty PL, Narayanan S, Gariepy J, Ranganathan S, Finn OJ. Vaccine against MUC1 Antigen Expressed in Inflammatory Bowel Disease and Cancer Lessens Colonic Inflammation and Prevents Progression to Colitis-Associated Colon Cancer. Cancer Prev Res (Phila Pa) 2010; 3: 438-46.
14. Osterrieder N, Kamil JP, Schumacher D, Tischer BK, Trapp S. Marek's disease virus: from miasma to model. Nat Rev Microbiol 2006; 4: 283-94.
15. Baigent SJ, Smith LP, Nair VK, Currie RJ. Vaccinal control of Marek's disease: current challenges, and future strategies to maximize protection. Vet Immunol Immunopathol 2006; 112: 78-86.
16. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 1348-55.
17. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006; 1: 23-61.
18. Strickland GT, El-Kamary SS, Klenerman P, Nicosia A. Hepatitis C vaccine: supply and demand. Lancet Infect Dis 2008; 8: 379-86.
19. Boyle P, Levin B. World Cancer Report. Lyon: IARC 2008.
20. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-50.
21. Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008; 26 Suppl 10: K53-K61.
22. Ault KA. Effect of prophylactic human papillomavirus L1 viruslike- particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861-8.
23. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693-702.
24. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-14.
25. Bosch FX. Broad-spectrum human papillomavirus vaccines: new horizons but one step at a time. J Natl Cancer Inst 2009; 101: 771-3.
26. De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer 2009; 45: 2632-9.
27. Michels KB, zur Hausen H. HPV vaccine for all. Lancet 2009; 374: 268-70.
28. Gardasil approved to prevent genital warts in men and boys. AIDS Patient Care STDS 2009; 23: 991.
29. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.
30. Franco EL. A new generation of studies of human papillomavirus DNA testing in cervical cancer screening. J Natl Cancer Inst 2009; 101: 1600-1.
31. Rees L, Tizard EJ, Morgan AJ, et al. A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 2009; 88: 1025-9.
32. Arora S, Czinn SJ. Vaccination as a method of preventing Helicobacter pylori-associated gastric cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1890-1.
33. Balfour HH, Jr. Epstein-Barr virus vaccine for the prevention of infectious mononucleosis--and what else? J Infect Dis 2007; 196: 1724-6.
34. Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 2007; 196: 1749-53.
35. Nasir L, Campo MS. Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids. Vet Dermatol 2008; 19: 243-54.
36. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006; 6: 204-16.
37. Spisek R, Dhodapkar MV. Immunoprevention of cancer. Hematol Oncol Clin North Am 2006; 20: 735-50.
38. Hayakawa Y, Rovero S, Forni G, Smyth MJ. Alphagalactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci USA 2003; 100: 9464-9.
39. Ambrosino E, Spadaro M, Iezzi M, et al. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 2006; 66: 7734-40.
40. Zhou P, Fang X, McNally BA, et al. Targeting lymphotoxinmediated negative selection to prevent prostate cancer in mice with genetic predisposition. Proc Natl Acad Sci USA 2009; 106: 17134-9.
41. Sfondrini L, Besusso D, Rumio C, et al. Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA. FASEB J 2002; 16: 1749-54.
42. Mastini C, Becker PD, Iezzi M, et al. Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice. Curr Cancer Drug Targets 2008; 8: 230-42.
43. Chin AI, Miyahira AK, Covarrubias A, et al. Toll-like receptor 3- mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res 2010; 70: 2595-603.
44. Boggio K, Nicoletti G, Di Carlo E, et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998; 188: 589-96.
45. Noguchi Y, Jungbluth A, Richards EC, Old LJ. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci USA 1996; 93: 11798-801.
46. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 155-68.
47. Katsumata M, Okudaira T, Samanta A, et al. Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat Med 1995; 1: 644-8.
48. Allen SD, Garrett JT, Rawale SV, et al. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol 2007; 179: 472-82.
49. Stagg J, Sharkey J, Pommey S, et al. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proc Natl Acad Sci USA 2008; 105: 16254-9.
50. Nanni P, Nicoletti G, De Giovanni C, et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 2001; 194: 1195-205.
51. De Giovanni C, Nicoletti G, Landuzzi L, et al. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res 2004; 64: 4001-9.
52. Quaglino E, Iezzi M, Mastini C, et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in Her-2/neu transgenic mice. Cancer Res 2004; 64: 2858-64.
53. Curcio C, Khan AS, Amici A, et al. DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Ther 2008; 15: 108-14.
54. Rolla S, Ria F, Occhipinti S, et al. ErbB2 DNA vaccine combined with Treg cell deletion enhances antibody response and reveals latent low-avidity T cells. Potential and limits of its therapeutic efficacy. J Immunol 2010; 184: 6124-32.
55. Nanni P, Landuzzi L, Nicoletti G, et al. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol 2004; 173: 2288-96.
56. Park JM, Terabe M, Sakai Y, et al. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 2005; 174: 4228-36.
57. Quaglino E, Rolla S, Iezzi M, et al. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J Clin Invest 2004; 113: 709-17.
58. Porzia A, Lanzardo S, Citti A, et al. Attenuation of PI3K/Aktmediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies. J Immunol 2010; 184: 4170-7.
59. Spadaro M, Ambrosino E, Iezzi M, et al. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neo-adjuvant IL-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res 2005; 11: 1941-52.
60. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54: 187-207.
61. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-37.
62. Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001; 83: 117-58.
63. Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 2008; 57: 1719-26.
64. Nanni P, Pupa SM, Nicoletti G, et al. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer 2000; 87: 186-94.
65. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008; 68: 3077-80.
66. Kmieciak M, Knutson KL, Dumur CI, Manjili MH. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol 2007; 37: 675-85.
67. Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol 2009; 10: 1179-87.
68. Lollini PL, Nicoletti G, Landuzzi L, De Giovanni C, Nanni P. New target antigens for cancer immunoprevention. Curr Cancer Drug Targets 2005; 5: 221-8.
69. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009; 420: 345-61.
70. Chiarle R, Martinengo C, Mastini C, et al. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med 2008; 14: 676-80.
71. Ait-Tahar K, Damm-Welk C, Burkhardt B, et al. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood 2010; 115: 3314-9.
72. Mastini C, Martinengo C, Inghirami G, Chiarle R. Anaplastic lymphoma kinase: an oncogene for tumor vaccination. J Mol Med 2009; 87: 669-77.
73. Anderson KS, Wong J, Vitonis A, et al. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev 2010; 19: 859-68.
74. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
75. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 2006; 124: 1111-5.
76. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253-70.
77. Bussolati B, Grange C, Sapino A, Camussi G. Endothelial cell differentiation of human breast tumour stem/progenitor cells. J Cell Mol Med 2009; 13: 309-19.
78. Nanni P, Nicoletti G, De Giovanni C, et al. Prevention of HER- 2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. Int J Cancer 2003; 105: 384-9.
79. De Giovanni C, Nicoletti G, Landuzzi L, et al. Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy. Vaccine 2009; 27: 2065-9.
80. Croci S, Nicoletti G, Landuzzi L, et al. Immunological prevention of a multigene cancer syndrome. Cancer Res 2004; 64: 8428-34.
81. Pannellini T, Spadaro M, Di CE, et al. Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. J Immunol 2006; 176: 7695-703.
82. De Giovanni C, Nicoletti G, Palladini A, et al. A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome. Hum Gene Ther 2009; 20: 453-64.
83. Finn OJ. Premalignant lesions as targets for cancer vaccines. J Exp Med 2003; 198: 1623-6.
84. Warren RL, Holt RA. A census of predicted mutational epitopes suitable for immunologic cancer control. Hum Immunol 2010; 71: 245-54.
85. Kurosawa Y. Comprehensive Identification of Tumor-associated Antigens via Isolation of Human Monoclonal Antibodies that may be Therapeutic. Immune Netw 2009; 9: 4-7.
86. Cavallo F, Calogero RA, Forni G. Are oncoantigens suitable targets for anti-tumour therapy? Nat Rev Cancer 2007; 7: 707-13.
87. Calogero RA, Quaglino E, Saviozzi S, Forni G, Cavallo F. Oncoantigens as anti-tumor vaccination targets: the chance of a lucky strike? Cancer Immunol Immunother 2008; 57: 1685-94.
88. Disis ML, Wallace DR, Gooley TA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009; 27: 4685-92.
89. Reipert BM, Tanneberger S, Pannetta A, et al. Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer? Cancer Immunol Immunother 2005; 54: 1038-42.
90. Finn OJ. Immunological weapons acquired early in life win battles with cancer late in life. J Immunol 2008; 181: 1589-92.
91. Hrelia P, Tanneberger S. Immunoprevention of cancer poses a challenge to pharmacological research. Pharmacol Res 1997; 35: 391-401.
92. Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 2007; 67: 1326-34.
93. Jacob JB, Kong YC, Nalbantoglu I, Snower DP, Wei WZ. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity. J Immunol 2009; 182: 5873-81.
94. Bridle BW, Li J, Jiang S, et al. Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen. J Immunol 2010; 184: 4269-75.
95. Nanni P, Nicoletti G, Palladini A, et al. Antimetastatic activity of a preventive cancer vaccine. Cancer Res 2007; 67: 11037-44.
96. Driggers L, Zhang JG, Newcomb EW, et al. Immunotherapy of pediatric brain tumor patients should include an immunoprevention strategy: a medical hypothesis paper. J Neurooncol 2010; 97: 159-69.
97. Ryu WS, Son GS. Cancer vaccines targeting HER2/neu for early breast cancer. J Breast Cancer 2010; 13: 5-13.
98. Lollini PL, De Giovanni C, Pannellini T, et al. Cancer immunoprevention. Future Oncol 2005; 1: 57-66.
99. Ladjemi MZ, Jacot W, Chardes T, Pelegrin A, Navarro-Teulon I. Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 2010; 59: 1295-312.
100. Berta GN, Sprio AE, Iezzi M, et al. A DNA Vaccine against ERBB2 Impairs Chemical Carcinogenesis in Random-Bred Hamsters. Cancer Prev Res (Phila) 2011; 4: 994-1001.
101. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55.
102. Reilly RT, Gottlieb MB, Ercolini AM, et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000; 60: 3569-76.
103. Nabekura T, Nagasawa T, Nakauchi H, Onodera M. An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2. Cancer Immunol Immunother 2008; 57: 611-22.
104. Esserman LJ, Lopez T, Montes R, et al. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol Immunother 1999; 47: 337-42.
105. Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 2000; 60: 3782-9.
106. Manjili MH, Wang XY, Chen X, et al. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 2003; 171: 4054-61.
107. Pupa SM, Iezzi M, Di Carlo E, et al. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res 2005; 65: 1071-8.
108. Cefai D, Morrison BW, Sckell A, et al. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer. Int J Cancer 1999; 83: 393-400.
109. Wagner S, Jasinska J, Breiteneder H, et al. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res Treat 2007; 106: 29-38.
110. Amici A, Venanzi FM, Concetti A. Genetic immunization against neu/erbB2 transgenic breast cancer. Cancer Immunol Immunother 1998; 47: 183-90.
111. Smorlesi A, Papalini F, Amici A, et al. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma. Vaccine 2006; 24: 1766-75.
112. Wang X, Wang JP, Maughan MF, Lachman LB. Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis. Breast Cancer Res 2005; 7: R145-R155.
113. Masuelli L, Focaccetti C, Cereda V, et al. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors. Int J Oncol 2007; 30: 381-92.
114. Sakai Y, Morrison BJ, Burke JD, et al. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res 2004; 64: 8022-8.
115. Steel JC, Ramlogan CA, Yu P, et al. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. Cancer Res 2010; 70: 1072-81.
116. Garrett JT, Rawale S, Allen SD, et al. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. J Immunol 2007; 178: 7120-31.
117. Rovero S, Amici A, Carlo ED, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165: 5133-42.
118. Cho HI, Niu G, Bradley N, Celis E. Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors. Cancer Immunol Immunother 2008; 57: 1695-703.
119. Jacob J, Radkevich O, Forni G, et al. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol 2006; 240: 96-106.
120. Holmgren L, Ambrosino E, Birot O, et al. A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci USA 2006; 103: 9208-13.
121. Masuelli L, Marzocchella L, Focaccetti C, et al. Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice. Cancer Immunol Immunother 2010; 59: 1247-58.
122. Tegerstedt K, Lindencrona JA, Curcio C, et al. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res 2005; 65: 5953-7.
123. Gallo P, Dharmapuri S, Nuzzo M, et al. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice. Int J Cancer 2007; 120: 574-84.
124. Quaglino E, Mastini C, Amici A, et al. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res 2010; 70: 2604-12.
125. Zeng J, Cai S, Yi Y, et al. Prevention of spontaneous tumor development in a ret transgenic mouse model by ret peptide vaccination with indoleamine 2,3-dioxygenase inhibitor 1-methyl tryptophan. Cancer Res 2009; 69: 3963-70.
126. Ye X, McCarrick J, Jewett L, Knowles BB. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigentransgenic mice. Proc Natl Acad Sci USA 1994; 91: 3916-20.
127. De Giovanni C, Croci S, Nicoletti G, et al. Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. Int J Cancer 2007; 121: 88-94.
128. Degl'Innocenti E, Grioni M, Boni A, et al. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol 2005; 35: 66-75.
129. Willimsky G, Blankenstein T. Sporadic immunogenic tumors avoid destruction by inducing T cell tolerance. Nature 2005; 437: 141-6.
130. Stahl S, Sacher T, Bechtold A, et al. Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma. Immunol Lett 2009; 123: 31-7.
131. Stewart TJ, Abrams SI. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol 2007; 179: 2851-9.
132. Papewalis C, Wuttke M, Seissler J, et al. Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer. Clin Cancer Res 2008; 14: 4298-305.
133. Wuttke M, Papewalis C, Meyer Y, et al. Amino acid-modified calcitonin immunization induces tumor epitope-specific immunity in a transgenic mouse model for medullary thyroid carcinoma. Endocrinology 2008; 149: 5627-34.
134. Mennuni C, Ugel S, Mori F, et al. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res 2008; 68: 9865-74.
135. Garcia-Hernandez ML, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 2008; 68: 861-9.
136. Iinuma T, Homma S, Noda T, et al. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J Clin Invest 2004; 113: 1307-17.
137. Vella LA, Yu M, Phillips AB, Finn OJ. Immunity against cyclin B1 tumor antigen delays development of spontaneous cyclin B1- positive tumors in p53 (-/-) mice. Ann N Y Acad Sci 2009; 1174: 68-73.
138. Vogt A, Chuang PT, Hebert J, et al. Immunoprevention of basal cell carcinomas with recombinant hedgehog-interacting protein. J Exp Med 2004; 199: 753-61.
139. Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 2002; 62: 6944-51.
140. Zeytin HE, Patel AC, Rogers CJ, et al. Combination of a poxvirusbased vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer Res 2004; 64: 3668-78.
141. Gritzapis AD, Voutsas IF, Lekka E, Papamichail M, Baxevanis CN. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells. Cancer Res 2010; 70: 2686-96.
142. Xia J, Tanaka Y, Koido S, et al. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol 2003; 170: 1980-6.
143. Mukherjee P, Basu GD, Tinder TL, et al. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 2009; 182: 216-24.